Healthcare IT Today February 14, 2022
Funding Round is Led by New Era Capital Partners and Includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech
Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in funding. The series C-2 funding round, led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.
Variantyx is poised to take advantage of the rapidly growing global precision oncology market with access to North America and Europe, the...
Today's Sponsors
Today's Sponsor